Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
2012
Background
Delivering affordable cancer care is becoming increasingly important. Bevacizumab (BEV) is a costly molecular targeted agent effective for a variety of cancer including lung cancer. The objective of this review is to assess published economic evaluation of BEV in the treatment of non-small cell lung cancer (NSCLC).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
13
Citations
NaN
KQI